Edwards Lifesciences (EW) Faces Investor Class Action Lawsuit Over TAVM Platform Disclosures, Deadline Pending – Hagens Berman

SAN FRANCISCO , Dec. 04, 2024 (GLOBE NEWSWIRE) -- Investors in Edwards Lifesciences Corporation (NYSE: EW) contend that the medical device giant misled them about the growth prospects of its core product, the Transcatheter Aortic Valve Replacement (TAVR) platform. A class action lawsuit has been filed, accusing the company of securities fraud and claiming that executives painted a misleading picture of TAVR's future growth potential. Hagens Berman urges Edwards Lifesciences Corporation investors who suffere ...